Close menu

January 27th, 2022 | 10:13 CET

Valneva, XPhyto, Peloton Interactive: What is next for pandemic stocks?

  • Biotechnology
Photo credits:

The pandemic is entering a new phase. Although incidences are rising towards the 1,000 mark, the population is largely relaxing. In the meantime, almost everyone knows someone who has fallen ill; as a rule, the scare is over quickly for those who have been vaccinated. In this article, we look at what this means for the stock market.

time to read: 3 minutes | Author: Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , XPHYTO THERAPEUTICS | CA98421R1055 , PELOTON INTE.A DL-_000025 | US70614W1009

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Valneva: What is the outlook for the hopeful Company?

    The Valneva share has recently lost ground. The European inactivated vaccine was eagerly awaited by many market participants in recent months. In the meantime, however, the air around the hopeful vaccine of many vaccination critics is out. The approval process for the French manufacturer's vaccine is currently underway within the EU. The vaccine may be approved before the end of the first quarter. Participants in the ongoing Phase III trial are already receiving the vaccine as a booster, but these data will no longer be included in the approval process in the short term. However, the data are not lost and could play a role in further approval procedures.

    A few days ago, it became known that Valneva's vaccine candidate probably also helps against the Omicron variant. However, the Company will not put its PS on the road until it is also approved. Since the proportion of unvaccinated people in Germany is still high, there is still sales potential for Valneva. In a market phase in which Corona profiteers are being punished across the board, the shares of the vaccine laggard are not the first choice.

    XPhyto: PCR-quality rapid tests gain in importance

    Another laggard is the share of the biotech XPhyto - at least as far as the share price is concerned, the value has hardly profited recently. Yet XPhyto offers precisely what could help in the current phase of the pandemic: Rapid PCR tests that promise laboratory-quality results within 25 minutes - and completely independent of location. In addition, XPhyto's Diagnostics business offers products to combat oral diseases and is researching innovative dosage forms. In this business area, the aim is to enable certain active ingredients to be better absorbed by the body if they are administered in the form of patches instead of tablets, for example. These approaches can, for example, ensure that the overall dose can be increased, which can, for example, reduce susceptibility to side effects. As a third pillar, XPhyto offers psychedelics for use against mental illness. Research of this kind is quite normal in the US but is viewed critically in Europe because some of the active ingredients are also considered narcotics.

    The share has lost ground in recent weeks, probably because PCR tests are now to be rationed in Germany. However, it remains to be seen to what extent these requirements can be implemented in practice. Since rapid tests are still considered unreliable, and experts warn of new virus variants, the pandemic is not yet over on the stock market. XPhyto's stock remains interesting, above all, because there are also countries where PCR tests have long been the gold standard, such as Austria. The research portal took a closer look at XPhyto a few months ago.

    Peloton: Now this too!

    A pandemic stock of the first hour is Peloton Interactive. When the epidemic was still comparatively young, Corona felt like a big "challenge" to many people. Resign and get fat or get through it was the name of the game. Many self-optimizers learned languages, an instrument or swung onto a spinning bike in the first few weeks. Peloton offers such a bike, including motivation from experienced trainers via stream. But recently, the stock dropped like a stone. Peloton's existing users also appear pandemic-weary. To make matters worse, a series character from "Sex and the City" has now "died" after a Peloton workout - purely fictitiously, of course. But this example shows that product placement can backfire. Peloton's stock is not very interesting at the moment. Spring is just around the corner in the northern hemisphere. Those who want to do sports will soon be doing so outside again. Incidence or not.

    While Peloton may have seen its highs, XPhyto and Valneva could go up again. The pandemic is not over yet, but it is changing its face. Speculative XPhyto, in particular, could react dynamically to new orders.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.